Bellicum Pharmaceuticals, Inc. (BLCM) News & Overview - Discounting Cash Flows
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM (NASDAQ)

BLCM's Business Model

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Sector & Industry Healthcare / Biotechnology
Website https://www.bellicum.com
CEO (Chief Executive Officer) David M. Maggio
Number of Employees
IPO date December 18, 2014

BLCM Latest News

Contact
CountryUS
Address3730 Kirby Drive
CityHouston
StateTX
Phone281 454 3424
Zip Code77098
Other Identifiers
CIK0001358403
ISINUS0794814048
CUSIP079481404
Open0.0801
Previous Close0.0801
Volume6.06 Thou.
Average Volume28.58 Thou.
Day’s Range0.0717 – 0.09
52 Week Range0.06-1.31
MA (50)0.1057822
MA (200)0.26351684
Market Cap778.3 Thou.
Shares Out.10.41 Mil.
Earnings DateMar 29, 2024
Beta
Last Dividend
EPS
PE

Industry Competitors for BLCM

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us